-

Shareholder Alert: Robbins LLP Announces Shareholder Class Action Against CURO Group Holdings, Corp. (CURO) Survives Motion to Dismiss

SAN DIEGO & WICHITA, Kan.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that CURO Group Holdings, Corp. (NYSE: CURO) may face damages caused by a pending securities lawsuit. CURO is a diversified consumer finance company, provides consumer finance to a range of underbanked consumers.

If you suffered a loss as a result of CURO's misconduct, click here.

Shareholder Class Action Alleging CURO Group Holdings, Corp. (CURO) Made Materially False and Misleading Statements Survives Motion to Dismiss

Investors filed a class action complaint against CURO for alleged violations of the Securities Exchange Act of 1934. According to the class action complaint, between July 31, 2018 and October 24, 2018, CURO consistently touted the ongoing success of transitioning its Canadian inventory products from Single-Pay Loans to Open-End Loans and reaffirmed its 2018 full-year financial guidance. Despite positive assurances regarding the transition, on October 24, 2018, CURO shocked investors with disappointing results for the Company's third quarter, including Canadian revenue that had decreased by $4.4 million, provision for losses that had increased by $8.7 million, and an adjusted EBITDA that decreased by $15.36 million. As a result, CURO revised its 2018 full-year guidance to include adjusted net income in the range of $88-$91 million compared to the previous range of $110-$116 million and an adjusted EBITDA in the range of $215-$218 million compared to its previous range of $245-$255 million. On this news, CURO's stock price plummeted $7.69, or almost 34%, to close at $15.18 per share. On December 3, 2019, U.S. District Court Judge John W. Lungstrum denied CURO's motion to dismiss plaintiffs' claims, paving the way for litigation to proceed.

CURO Group Holdings, Corp. (CURO) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leonid Kandinov
Robbins LLP
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom